RiverVest https://validator.w3.org/feed/docs/rss2.html Team Portfolio Home Accessibility Statement Newsletter Avalyn Pharma, Inc. Xilio Therapeutics Sparrow Pharmaceuticals OxaluRx, Inc. Mirum Pharmaceuticals MaxWell Biomedical InterVene, Inc. Glycomine, Inc. Flex Vascular, Inc. Engrail Therapeutics, Inc. Bonum Therapeutics, Inc. Biolinq Allotera Therapeutics, Inc. Alleviant Medical, Inc. Arexera Therapeutics About News Jeff Seitz Atalanta Therapeutics: Reaching the Unreachable in Huntington’s Disease Niall O’Donnell, Ph.D. CASE STUDY: GOOD THERAPEUTICS NEWS / RiverVest Mourns Passing of Bradley T. Keller, PhD, Former RiverVest Entrepreneur-in-Residence Thomas C. Melzer Pascal Krotee Karen Spilizewski Jay W. Schmelter Isaac Zike, Ph.D. RIVERVEST NEWS: June Newsletter Case Studies Portfolio News RIVERVEST NEWS: February Newsletter Portfolio Company Bluejay Therapeutics to be Acquired by Mirum Pharmaceuticals ANNOUNCEMENT / Teleflex to Acquire Standard Bariatrics Nafiseh Masoumi JPM 2026 Recap: Signals Are Getting Clearer Lumena Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. Bluejay Therapeutics Year in Review 2025 RIVERVEST NEWS: June Newsletter With $115 Million in Hand, Biotech Startup Eyes the Finish Line Peter Tontonoz, M.D., Ph.D. Could Excess Cortisol Be Driving Type 2 Diabetes Resistance? NEWS / RiverVest Mourns Passing of Ronald T. Borchardt, PhD RiverVest Venture Partners Welcomes Brandon Cohen as Analyst